Dr. Ramdahl's presentation, which is scheduled for Tuesday, November 18, 2008 at 4:40 p.m., will provide a corporate overview including comments on the Company's ALSYMPCA phase III clinical trial in hormone refractory prostate cancer.
For further information, please contact
Dr. Thomas Ramdahl, President +47 23 00 79 90 / +47 913 91 458 (mob) and CEO +47 23 00 79 84 / +47 906 56 525 (mob) Øystein Soug, CFO email@example.com
For international enquiries: +44 207 638 9571 Mark Swallow/Helena firstname.lastname@example.org Galilee/David Dible Citigate Dewe Rogerson
About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, has commenced phase III clinical trials in hormone-refractory prostate cancer based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Stock Identifier: XOSL.ALGETA